2023 annual financial data

Metagenomi Therapeutics 2023 Net margin

Direct answer

Net margin was -152.5%.

Operating income was -78,492,000 USD and net income was -68,255,000 USD.
Operating cash flow was -91,409,000 USD.

Get free Metagenomi Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
44,756,000 USD
Operating income
-78,492,000 USD
Net income
-68,255,000 USD
Operating cash flow
-91,409,000 USD